radiopharmaceuticals
-
RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials
RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.
-
Cancer Biotech Abdera Reveals $142M for Better Antibody-Based Radiation Drugs
Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Novartis Puts Up $50M to Steer Bicycle Therapeutics’ Tech Into New Cancer Meds
Novartis is partnering with Bicycle Therapeutics to see if the biotech’s technology can be used to develop better, more targeted radiopharmaceuticals. The deal covers two targets that were not disclosed.
-
Curie Therapeutics unveils $75M to widen scope of radiopharmaceuticals for cancer
Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.
-
Why contract development and manufacturing for radiopharma may be a smart move
Radiopharmaceuticals are highly specialized and require equipment, facilities, personnel, licensing and training that is significantly different from traditional pharmaceutical manufacturing.